Aadi Bioscience rises on narrower Q4 loss
28/03/2023 13:51
** Shares of cancer therapy developer Aadi Bioscience Inc
AADI.O up 4.83% at $7.60 in premarket trading
** Posts Q4 net loss of $0.52 per share vs $0.77 loss per
share last year urn:newsml:reuters.com:*:nTUA35CWNZ
** Reports revenue of $5.2 mln, compared with a $1 mln
revenue in a year earlier quarter
** CFO Scott Giacobello says "2022 was a year marked by
successive milestones with the launch of FYARRO, the start of
the PRECISION 1 trial, strengthening our balance sheet with a
$72.5 million financing, taking our cash runway into 2025"
** Up to Monday's close, stock had fallen ~43% YTD
(Reporting by Amna Karimi in Bengaluru)
((Amna.Karimi@thomsonreuters.com; +91 8083261226;))